Event Information

*Time：*February 26, 2016 (Friday)
placeTRPMA Conference Room

TRPMA invited Ms Hsu Yu-Chen, a senior industry analyst of the ITIS, to give a special talk about the industry trends and the changes in the pharmaceutical policies and regulations in China. Ms Hsu analysed the changes of the industry environment, the current situations, future trends and opportunities across the Strait.

As the Chinese government increases health spending, the disposable income rises and the population is ageing, the healthcare demand also increases.

The Chinese government is keen to reform its pharmaceutical regulatory systems. For example, actions have been taken to standardize the drug review standards, to improve the drug procurement systems, to reform drug prices and to upgrade drug review standards, etc. The government also encourages innovation by granting fast-track review to innovative drugs and new drugs for unmet medical needs. The biopharmaceutical industry is one of the key industries according to the Chinese government’s plan. The Chinese government has been investing hugely in the development of precision medicine. It plans to promote a new commercial model which links the internet with the healthcare industry.

Ms Hsu pointed out that, under the “13th 5 Year Plan”, a reform of the pharmaceutical review system is underway. It will have a profound impact on the industry. The key development areas for the next 5 years are: target treatment, antibody, emerging healthcare, regenerative medicine and personalized medicine. The government is going to improve the healthcare in the third-tier cities.